We had earlier reported on why 2018 was the year of healthcare IPOs. It seems the trend is continuing into this year as well. Two healthcare unicorns have already priced their IPOs this year, and both of them happened this week.
San Diego-based biotech firm Gossamer Bio, which focuses on immunology and oncology drugs, priced 17.25 million shares late on Thursday at $16 apiece.
The company, which has three experimental drugs under development, raised $276 million through the initial public offering. The stock started trading on Nasdaq under the symbol GOSS on Friday.
Bank of America Merrill Lynch, Evercore ISI, Barclays and SVB Leerink were the underwriters of the public listing.
The biotech unicorn, which is headed by former Receptos executive Sheila Gujrathi, will use the raised amount to advance its flagship asthma drug, as well as other investigational therapies.
On Wednesday, South San Francisco-based Alector priced 9.25 million shares at $19 apiece, raising $176 million in the first IPO since the 35-day federal government shutdown. The stock, which started trading on Nasdaq under the ticker ALEC on Thursday, ended the day over 5% in red.
Also read: These 2 tech startups may follow Spotify’s method of direct listing over IPO in 2019
Notably, Alector specializes in brain disorders and approaches Alzheimer’s Disease as an immune system disorder. The company, which is headed by former Genentech scientist Arnon Rosenthal, will use the net proceeds to develop new drugs as well as for the clinical trials of the experimental ones.
Alector had earlier raised funding from Amgen Inc, Abbvie and GV (Google Ventures). Bank of America, Barclays, Cowen Inc, and Morgan Stanley were the underwriters of the IPO.
We’re on Flipboard! Follow us to receive the latest stock market, earnings and financial news at your fingertips
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to
Key highlights from Exxon Mobil Corporation’s (XOM) Q3 2024 earnings results
Exxon Mobil Corporation (NYSE: XOM) reported its third quarter 2024 earnings results today. Total revenues and other income remained relatively flat at $90 billion compared to the same period a
AAPL Earnings: Apple Q4 2024 sales rise 6% YoY, beat estimates
Apple Inc. (NASDAQ: AAPL) reported an increase in revenues for the fourth quarter of 2024. The top line came in above estimates. The gadget giant generated revenues of $94.9 billion